Skip to main content
OpenTrials
Completed

NCT Number: NCT02884245

Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa

E2 given in late luteal phase can be extended beyond the onset of menses for a period of at least eight days before the start of the stimulation, allowing scheduling of stimulation in order to limit oocytes retrievals during weekends .

Administration of corifollitropin alfa, a Follicule stimulating Hormone (FSH) with extended release kinetics, seems particularly interesting for a synchronous recruitment of follicles after homogenization of the cohort.

The objective of this study is to evaluate the impact on the response to ovarian stimulation with corifollitropin alfa of E2 scheduling versus no scheduling for women over 38 years, age at which declining of ovarian reserve usually begins. The management of these patients in terms of organization of the center is also evaluated.

The scheduling of IVF cycles represents a double benefit. On one hand, to enable a "synchronization" of the follicular cohort for a best response and a higher number of mature oocytes. On the other hand, a more efficient organization for both the center (avoiding retrievals on weekends and public holidays, organize and distribute equally the activity, reduce cost operations) and couples (personal and professional organization).

Completed

Looking for future studies?

Notify Me

Key information

Age range

38 year–47 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Hôpital Jean Verdier, Bondy, France

Loading trial locations.

About this study

With advanced age, ovarian reserve decreases, follicular cohort becomes heterogeneous under the influence of higher FSH rise in late luteal phase. It has been shown that estrogens (E2) taken in the late luteal phase homogenized follicular cohort by inhibiting inter cycle FSH peak ,and that this inhibition is immediately reversible after discontinuation of treatment .

E2 given in late luteal phase can also be extended beyond the onset of menses for a period of at least eight days before the start of the stimulation, allowing scheduling of stimulation in order to limit oocytes retrievals during weekends . A prospective randomized study comparing E2 scheduling and no scheduling has shown that there was no difference in birth rate in a population of normo-responders women . While in these patients, the number of oocytes was not different in the two arms, a recent pilot study founded a significant increase in the number of oocytes retrieved after E2 luteal phase priming compared to the absence of priming in a population of poor responders .

In 2013, a report of the French governmental BioMedicine Agency warned about the thrombo-embolic risk associated with the use of the contraceptive pill for IVF scheduling, especially in women over 35.

Administration of corifollitropin alfa, an FSH with extended release kinetics, seems particularly interesting for a synchronous recruitment of follicles after homogenization of the cohort. In the Pursue study, an equivalent efficacy has been shown with the daily administration of 300 IU FSH and corifollitropin alfa in patients over 35 years .

The objective of this study is to evaluate the impact of the response to ovarian stimulation with corifollitropin alfa of E2 scheduling versus no scheduling for women over 38 years, age at which declining of ovarian reserve usually begins. The management of these patients in terms of organization of the center is also evaluated.

The scheduling of IVF cycles represents a double benefit. On one hand, to enable a "synchronization" of the follicular cohort for a best response and a higher number of mature oocytes. On the other hand, a more efficient organization for both the center (avoiding retrievals on weekends and public holidays, organize and distribute equally the activity, reduce cost operations) and couples (personal and professional organization). This can be done with pills but there are controversial data on its impact on the chances of birth. It has been shown that estrogen scheduling provides opportunities for success equivalent to the absence of scheduling for patients with good prognosis . If this study confirms the initial hypothesis, it will show that a less favorable public can profit from the benefits of scheduling by estrogen on both the organization of the attempt and the chances of pregnancy through better ovarian response.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient of 38 years or more
  • Planned in invitro fertilization or intracytoplasmic sperm injection rank 1 or 2 (rank = retrieval with transfer)
  • With regular cycles from 26 to 35 days
  • Weight > 50 kg and body mass index< or equal to 32
  • Affiliation to the general system of French social security and reimbursement for fertility problems

Exclusion criteria

  • Irregular cycles and/or polycystic ovarian syndrome
  • Previous History of ovarian hyperstimulation syndrome
  • Rank puncture > 2
  • Uterine malformation
  • Presence of hydrosalpinges
  • Endometriosis stage III or IV

Treatment and study plan

estrogens

Drug

The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses

Primary outcomes

  1. Number of selected oocytes

    Time frame: At time of ovarian puncture

Secondary outcomes

  1. Number of days of pretreatment

    Time frame: From inclusion visit date to the beginning of stimulation, up to 15 days

  2. Cancellation rate

    Time frame: From date of inclusion visit until the date of embryo transfer, up to 90 days

  3. Number of days of antagonist

    Time frame: From date of stimulation until the date of the trigger, up to 30 days

  4. The day of the trigger

    Time frame: At time of the trigger

  5. Estradiol rate

    Time frame: 8 days from the beginning of stimulation and the day of the trigger

  6. Luteinizing hormone rate

    Time frame: 8 days from the beginning of stimulation and the day of the trigger

  7. Progesterone rate

    Time frame: 8 days from the beginning of stimulation and the day of the trigger

  8. Follicles number > 10 mm

    Time frame: 8 days from the beginning of stimulation

  9. Follicles number > 14 mm

    Time frame: From 1 day before the day of trigger or the day of trigger

  10. Number of oocytes in metaphase 2

    Time frame: At time of ovarian puncture

  11. Total number of embryos with good quality

    Time frame: At time of fertilization procedure

  12. early pregnancy

    Time frame: 14 days after embryo transfer

    Beta Human chorionic gonadotropin>100 U/l

  13. ongoing pregnancy rate

    Time frame: 12 weeks after embryo transfer

    on ultrasound procedure

  14. miscarriage before 12 weeks of amenorrhea

    Time frame: From embryo transfer to 12 weeks after embryo transfer

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Intercommunal Creteil

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa in Women Older Than 38 Years Old Undergoing in Vitro Fertilization

Acronym: PRESCORI

Important dates

Study start
2016
Primary completion
2022
Study completion
2023
First posted
Aug 30, 2016
Registry last updated
Feb 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.